The Development of Pharmacological Therapies for Alzheimer’s Disease

被引:0
|
作者
Ping Lin
Junyu Sun
Qi Cheng
Yue Yang
Dennis Cordato
Jianqun Gao
机构
[1] Shanghai Mental Health Center,Department of Medical Laboratory
[2] Shanghai Jiao Tong University School of Medicine,Department of Psychosis, Institute of Psychiatry, Psychology and Neuroscience
[3] King’s College London,Department of Neurology and Neurophysiology
[4] Liverpool Hospital,Stroke and Neurology Research Group
[5] Ingham Institute for Applied Medical Research,Brain and Mind Centre, Central Clinical School
[6] the University of Sydney,undefined
来源
Neurology and Therapy | 2021年 / 10卷
关键词
Alzheimer’s disease; Disease-modifying therapy; Symptomatic treatment; Clinical trial;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that currently has no cure. The aged population is growing globally, creating an urgent need for more promising therapies for this debilitating disease. Much effort has been made in recent decades, and the field is highly dynamic, with numerous trials. The main focus of these trials includes disease modification and symptomatic treatment. Some have shown beneficial outcomes, while others have shown no significant benefits. Here, we cover the outcome of recently published AD clinical trials, as well as the mechanism of action of these therapeutical agents, to re-think drug development strategies and directions for future studies.
引用
收藏
页码:609 / 626
页数:17
相关论文
共 50 条
  • [41] Current and Emerging Therapies for Alzheimer's Disease
    Nygaard, Haakon B.
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1480 - 1489
  • [42] Future combination therapies in Alzheimer's disease
    Giacobini, E
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S281 - S281
  • [43] Noradrenergic therapies for apathy in Alzheimer's disease?
    Husain, Masud
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (02): : 93 - 93
  • [44] NON PHARMACOLOGICAL INTERVENTIONS FOR ALZHEIMER'S DISEASE
    Tsolaki, Magda
    NEUROBIOLOGY OF AGING, 2016, 39 : S27 - S27
  • [45] Pharmacological strategies for the prevention of Alzheimer's disease
    Doraiswamy, PM
    Xiong, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (01) : 1 - 10
  • [46] Alzheimer's Disease: Cellular and Pharmacological Aspects
    Emiliano Aranda-Abreu, Gonzalo
    Rojas-Duran, Fausto
    Elena Hernandez-Aguilar, Maria
    Herrera-Covarrubias, Deissy
    Donaji Chi-Castaneda, Lizbeth
    Rebeca Toledo-Cardenas, Maria
    Manuel Suarez-Medellin, Jorge
    GERIATRICS, 2024, 9 (04)
  • [47] Alzheimer's disease: Pharmacological treatment and management
    Rivas-Vazquez, RA
    Carrazana, EJ
    Rey, GJ
    Blais, MA
    Racher, DA
    CLINICAL NEUROPSYCHOLOGIST, 2000, 14 (01) : 93 - 109
  • [48] Pharmacological Potential of Cilostazol for Alzheimer's Disease
    Ono, Kenjiro
    Tsuji, Mayumi
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [49] Update on the Pharmacological Treatment of Alzheimer's Disease
    Massoud, Fadi
    Gauthier, Serge
    CURRENT NEUROPHARMACOLOGY, 2010, 8 (01) : 69 - 80
  • [50] Alzheimer's disease: Progress in the development of anti-amyloid disease-modifying therapies
    Christensen, Daniel D.
    CNS SPECTRUMS, 2007, 12 (02) : 113 - +